Table 2.
Drug therapy and coexisting conditions at the baseline.
| Variables | Group I N (53) | Group II N (76) | Total for all Patients N (129) |
|---|---|---|---|
| Use of hypoglycemic agents | |||
| Metformin + Glibenclamide | 31 (58.5) | 43 (56.8) | 74 (57.4) |
| Metformin + Glimipride | 16 (30.2) | 21(27.6) | 37 (28.7) |
| Metformin + Gliclazide | 5 (9.4) | 10 (13.1) | 15 (11.6) |
| Metformin + Repaclinide | 1 (1.9) | 0 | 1 (0.8) |
| Metformin + Pioglitazone | 0 | 0 | 0 |
| Metformin + Roziglitazone | 1 (1.9) | 1 (1.3) | 2 (1.6) |
| Coexisting conditions | |||
| Neuropathy | 4(5.88) | 16(21.1) | 20 (15.5) |
| Retinopathy | 1(1.47) | 12(15.8) | 13 (10.1) |
| Diabetic foot ulcer | 0 | 0 | 0 |
| Diabetic ketoacidosis | 0 | 5(6.6) | 5 (3.9) |
| Impotence | 4(5.88) | 4(5.3) | 8 (6.2) |
| Ischemic heart disease | 5(7.35) | 2(2.6) | 7 (5.4) |
| Cerebrovascular Aneurism | 1(1.47) | 5(6.6) | 6 (4.7) |
| Depression | 4(5.88) | 7(9.2) | 11 (8.5) |